Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with met...
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
About this item
Full title
Author / Creator
Stupp, Roger, Prof , Hegi, Monika E, PhD , Gorlia, Thierry, PhD , Erridge, Sara C, MD , Perry, James, MD , Hong, Yong-Kil, Prof , Aldape, Kenneth D, Prof , Lhermitte, Benoit, MD , Pietsch, Torsten, Prof , Grujicic, Danica, Prof , Steinbach, Joachim Peter, Prof , Wick, Wolfgang, Prof , Tarnawski, Rafał, Prof , Nam, Do-Hyun, Prof , Hau, Peter, Prof , Weyerbrock, Astrid, MD , Taphoorn, Martin J B, Prof , Shen, Chiung-Chyi, MD , Rao, Nalini, MD , Thurzo, László, MD , Herrlinger, Ulrich, MD , Gupta, Tejpal, MD , Kortmann, Rolf-Dieter, Prof , Adamska, Krystyna, MD , McBain, Catherine, MD , Brandes, Alba A, MD , Tonn, Joerg Christian, Prof , Schnell, Oliver, MD , Wiegel, Thomas, Prof , Kim, Chae-Yong, MD , Nabors, Louis Burt, MD , Reardon, David A, MD , van den Bent, Martin J, Prof , Hicking, Christine, MSc , Markivskyy, Andriy, MD , Picard, Martin, PhD , Weller, Michael, Prof , for the European Organisation for Research and Treatment of Cancer (EORTC) , the Canadian Brain Tumor Consortium, and the CENTRIC study team , European Organisation for Research and Treatment of Cancer (EORTC) , Canadian Brain Tumor Consortium and CENTRIC study team
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background Cilengitide is a selective αvβ3 and αvβ5 integrin inhibitor. Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in combination with standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumours with methylated MGMT promoter). We aimed...
Alternative Titles
Full title
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Authors, Artists and Contributors
Author / Creator
Hegi, Monika E, PhD
Gorlia, Thierry, PhD
Erridge, Sara C, MD
Perry, James, MD
Hong, Yong-Kil, Prof
Aldape, Kenneth D, Prof
Lhermitte, Benoit, MD
Pietsch, Torsten, Prof
Grujicic, Danica, Prof
Steinbach, Joachim Peter, Prof
Wick, Wolfgang, Prof
Tarnawski, Rafał, Prof
Nam, Do-Hyun, Prof
Hau, Peter, Prof
Weyerbrock, Astrid, MD
Taphoorn, Martin J B, Prof
Shen, Chiung-Chyi, MD
Rao, Nalini, MD
Thurzo, László, MD
Herrlinger, Ulrich, MD
Gupta, Tejpal, MD
Kortmann, Rolf-Dieter, Prof
Adamska, Krystyna, MD
McBain, Catherine, MD
Brandes, Alba A, MD
Tonn, Joerg Christian, Prof
Schnell, Oliver, MD
Wiegel, Thomas, Prof
Kim, Chae-Yong, MD
Nabors, Louis Burt, MD
Reardon, David A, MD
van den Bent, Martin J, Prof
Hicking, Christine, MSc
Markivskyy, Andriy, MD
Picard, Martin, PhD
Weller, Michael, Prof
for the European Organisation for Research and Treatment of Cancer (EORTC)
the Canadian Brain Tumor Consortium, and the CENTRIC study team
European Organisation for Research and Treatment of Cancer (EORTC)
Canadian Brain Tumor Consortium
CENTRIC study team
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1751230446
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751230446
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(14)70379-1
